FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to pulmonology, and can be used in treating asthma. Methods of the invention involve subcutaneous administration of 30 mg of benralizumab or its antigen-binding fragment subcutaneously once every four weeks for twelve weeks, and then once every eight weeks.
EFFECT: using the inventions makes it possible to improve pulmonary function in the patients with asthma by increasing the forced expiratory volume in one second.
14 cl, 4 tbl, 9 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR REDUCING EXACERBATION RATES OF ASTHMA USING OF BENRALIZUMAB | 2014 |
|
RU2676333C2 |
| METHODS FOR NORMALIZING ASTHMA SYMPTOMS USING BENRALIZUMAB | 2014 |
|
RU2728578C2 |
| METHODS OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH USE OF BENRALIZUMAB | 2014 |
|
RU2706729C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST | 2018 |
|
RU2793745C2 |
| METHODS OF TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2734490C2 |
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
| DIAGNOSTICS AND TREATMENT METHODS ASSOCIATED WITH TH2 INHIBITION | 2011 |
|
RU2737245C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2013 |
|
RU2690675C2 |
| METHODS FOR TREATING NASAL POLYPOSIS BY ADMINISTERING IL-4R ANTAGONIST | 2014 |
|
RU2674680C2 |
